Prostate Cancer Trial Landscape (June 2026)

Last updated: Jun 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Recently Updated Trials

NCT	Phase	Title	Mechanism
NCT06402357	2	High Intensity Focused Ultrasound in Prostate Cancer	Unknown mechanism
NCT06085729	1, 2	Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)	Arginine depletion via arginine deiminase -- metabolic enzyme depletion + Microtubule inhibition (cabazitaxel) + DNA crosslinking (carboplatin)
NCT05045066	1	Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients	Vitamin D receptor -- vitamin D supplementation
NCT06855277	3	Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC	PSMA + Androgen receptor -- targeted alpha therapy + androgen receptor pathway inhibitor
NCT07574541	2	Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance	PSA, MUC-1, Brachyury -- recombinant adenoviral vaccine; IL-15 receptor -- superagonist (immunotherapy)

Top Sponsors

Sponsor	Recruiting trials
University Health Network, Toronto	22
Mayo Clinic	15
M.D. Anderson Cancer Center	15
National Cancer Institute (NCI)	14
Memorial Sloan Kettering Cancer Center	14

Geographic Distribution

Countries/regions with the most active trial sites for prostate cancer. A multi-site trial is counted once per country/region.

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

Start	NCT	Title	Mechanism
Mar 2028	NCT05896371	A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy	Prostate-specific membrane antigen (PSMA) -- radioligand therapy with lutetium-177 labeled PSMA ligand
Jul 2026	NCT07581184	A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer	PSMA -- targeted alpha-particle radioligand therapy
Jun 5, 2026	NCT06906471	A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS	PSMA -- fluorescent histopathology agent
Jun 1, 2026	NCT07495293	Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer	Carbon ions -- ultra-hypofractionated carbon ion radiotherapy
Jun 1, 2026	NCT07543055	A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread	PSCA -- chimeric antigen receptor T-cell therapy (CAR-T)
Jun 2026	NCT07316686	Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma	Prostate-Specific Membrane Antigen (PSMA) -- targeted radioligand therapy with 177Lu-PSMA-I&T combined with docetaxel chemotherapy
Jun 2026	NCT06616155	Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	JAK1/2 + Androgen receptor -- kinase inhibition + pathway inhibition (JAK inhibitor + AR pathway inhibitor)
May 25, 2026	NCT07594106	REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma	PSMA + 4-1BB -- bispecific antibody; PD-1 -- immune checkpoint inhibitor; PSMA + CD3 -- bispecific antibody

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.